A recent intriguing and promising approach in the field of dementia concerns the use of advanced neuroimaging techniques in association with neuropsychological evaluation and quantification of biological markers to identify subjects with high risk of developing AD in preclinical condition (i.e., Apolipoprotein E4-APOE 4 carriers) [39, 40]. This evidence concerns the gene APOE and Alzheimer disease.